- Home
- HNRG vs FLGT Comparison
HNRG vs FLGT Comparison
Compare HNRG & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- FLGT
- Stock Information
- Founded
- HNRG 1949
- FLGT 2011
- Country
- HNRG United States
- FLGT United States
- Employees
- HNRG N/A
- FLGT N/A
- Industry
- HNRG Coal Mining
- FLGT Medical Specialities
- Sector
- HNRG Energy
- FLGT Health Care
- Exchange
- HNRG Nasdaq
- FLGT Nasdaq
- Market Cap
- HNRG 823.6M
- FLGT 697.3M
- IPO Year
- HNRG N/A
- FLGT 2016
- Fundamental
- Price
- HNRG $20.77
- FLGT $22.60
- Analyst Decision
- HNRG Strong Buy
- FLGT Buy
- Analyst Count
- HNRG 4
- FLGT 3
- Target Price
- HNRG $20.00
- FLGT $25.33
- AVG Volume (30 Days)
- HNRG 473.7K
- FLGT 184.0K
- Earning Date
- HNRG 11-10-2025
- FLGT 11-07-2025
- Dividend Yield
- HNRG N/A
- FLGT N/A
- EPS Growth
- HNRG N/A
- FLGT N/A
- EPS
- HNRG N/A
- FLGT N/A
- Revenue
- HNRG $419,451,000.00
- FLGT $303,223,000.00
- Revenue This Year
- HNRG $11.19
- FLGT $15.19
- Revenue Next Year
- HNRG $4.79
- FLGT $10.58
- P/E Ratio
- HNRG N/A
- FLGT N/A
- Revenue Growth
- HNRG N/A
- FLGT 4.31
- 52 Week Low
- HNRG $8.13
- FLGT $14.57
- 52 Week High
- HNRG $22.44
- FLGT $24.64
- Technical
- Relative Strength Index (RSI)
- HNRG 54.84
- FLGT 44.42
- Support Level
- HNRG $19.92
- FLGT $23.15
- Resistance Level
- HNRG $21.24
- FLGT $23.86
- Average True Range (ATR)
- HNRG 1.00
- FLGT 0.65
- MACD
- HNRG -0.07
- FLGT -0.14
- Stochastic Oscillator
- HNRG 45.74
- FLGT 6.30
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.